Shancheng Ren, MD,PhD
Shanghai Changzheng Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shancheng Ren, MD,PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:01 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06895811 · Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPCShanghai Changzheng Hospital · active not recruiting · Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Early Ph1NCT06866548 · Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate CancerShanghai Changzheng Hospital · active not recruiting · mCRPC · principal investigator
- Early Ph1NCT06586658 · Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal CellsShanghai Changzheng Hospital · suspended · Renal Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.